Eyepoint Pharmaceuticals Inc
General ticker "EYPT" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $451.4M
Eyepoint Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -29.9%.
Estimated limits based on current volatility of 4.0%: low 6.93$, high 7.51$
Factors to consider:
- US accounted for 97.8% of revenue in the fiscal year ended 2022-12-31
- Current price 28.3% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [10.12$, 22.49$]
- 2024-12-30 to 2025-12-30 estimated range: [8.01$, 18.57$]
Financial Metrics affecting the EYPT estimates:
- Negative: Non-GAAP EPS, $ of -1.83 <= 0.10
- Negative: Operating profit margin, % of -61.55 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of 0.29 <= 2.35
- Positive: Interest expense per share, $ of 0.03 <= 0.14
- Positive: Industry inventory ratio change (median), % of -2.41 <= -0.39
Short-term EYPT quotes
Long-term EYPT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $36.94MM | $41.40MM | $46.02MM |
| Operating Expenses | $92.22MM | $141.04MM | $121.08MM |
| Operating Income | $-55.28MM | $-99.64MM | $-75.07MM |
| Non-Operating Income | $-3.14MM | $-2.62MM | $4.36MM |
| Interest Expense | $5.50MM | $3.19MM | $1.25MM |
| R&D Expense | $28.50MM | $49.64MM | $64.66MM |
| Income(Loss) | $-58.42MM | $-102.25MM | $-70.71MM |
| Taxes | $0.00MM | $0.00MM | $0.08MM |
| Profit(Loss) | $-58.42MM | $-102.25MM | $-70.80MM |
| Stockholders Equity | $184.38MM | $96.37MM | $266.32MM |
| Inventory | $3.62MM | $2.89MM | $3.91MM |
| Assets | $263.37MM | $180.36MM | $355.18MM |
| Operating Cash Flow | $-50.10MM | $-65.00MM | $1.88MM |
| Capital expenditure | $0.16MM | $2.15MM | $3.48MM |
| Investing Cash Flow | $-33.12MM | $-17.27MM | $-3.31MM |
| Financing Cash Flow | $216.90MM | $-0.69MM | $187.07MM |
| Earnings Per Share* | $-2.22 | $-3.34 | $-1.82 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.